These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 9844778)

  • 1. Beneficial effect on bone density in male osteoporosis of postmenopausal osteoporosis treatment (fluoride, etidronate, and calcitriol).
    Laroche M; Andrieu V; Constantin A; Mazières B
    Clin Exp Rheumatol; 1998; 16(6):760. PubMed ID: 9844778
    [No Abstract]   [Full Text] [Related]  

  • 2. Calcium, vitamin D and etidronate for the prevention and treatment of corticosteroid-induced osteoporosis in patients with rheumatic diseases.
    Loddenkemper K; Grauer A; Burmester GR; Buttgereit F
    Clin Exp Rheumatol; 2003; 21(1):19-26. PubMed ID: 12673885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study.
    Gürlek A; Bayraktar M; Gedik O
    Calcif Tissue Int; 1997 Jul; 61(1):39-43. PubMed ID: 9192511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of male osteoporosis.
    Cortet B; Vasseur J; Grardel B; Catanzariti L; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 May; 68(3):252-6. PubMed ID: 11394626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women.
    Masud T; Mulcahy B; Thompson AV; Donnelly S; Keen RW; Doyle DV; Spector TD
    Ann Rheum Dis; 1998 Jun; 57(6):346-9. PubMed ID: 9771208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of etidronate and sequential monofluorophosphate in severe postmenopausal osteoporosis: a pilot study.
    Ringe JD; Dorst A; Faber H; Kipshoven C; Rovati LC; Setnikar I
    Rheumatol Int; 2005 May; 25(4):296-300. PubMed ID: 15770482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of osteoporosis in men with fluoride alone or in combination with bisphosphonates.
    Ringe JD; Rovati LC
    Calcif Tissue Int; 2001 Oct; 69(4):252-5. PubMed ID: 11730262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
    N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical experience with etidronate in osteoporosis.
    Ryan PJ; Fogelman I
    Clin Rheumatol; 1994 Sep; 13(3):455-8. PubMed ID: 7835009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study.
    Lyritis GP; Tsakalakos N; Paspati I; Skarantavos G; Galanos A; Androulakis C
    Clin Rheumatol; 1997 Jun; 16(4):354-60. PubMed ID: 9259248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Present and future of osteoporosis therapy.
    Seeman E; Tsalamandris C; Bass S; Pearce G
    Bone; 1995 Aug; 17(2 Suppl):23S-29S. PubMed ID: 8579894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Only bone densitometry answers this question. How stable are your patients' bones?].
    Neumaier J
    MMW Fortschr Med; 2006 May; 148(18):14. PubMed ID: 16736678
    [No Abstract]   [Full Text] [Related]  

  • 15. Cyclic oral phosphate and etidronate increase femoral and lumbar bone mineral density and reduce lumbar spine fracture rate over three years.
    Silberstein EB; Schnur W
    J Nucl Med; 1992 Jan; 33(1):1-5. PubMed ID: 1730972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T; McGuigan L; Barbagallo S; Bryant C
    Am J Med; 1995 May; 98(5):459-63. PubMed ID: 7733124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J; Takeda T; Ichimura S; Matsu K; Uzawa M
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evidence and utility of etidronate for the treatment of osteoporosis].
    Takada J; Iba K; Yamashita T; Yoshizaki T
    Clin Calcium; 2008 Oct; 18(10):1427-33. PubMed ID: 18830039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
    MMW Fortschr Med; 2004 Aug; 146(31-32):53. PubMed ID: 15529718
    [No Abstract]   [Full Text] [Related]  

  • 20. [Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
    MMW Fortschr Med; 2004 May; 146(21):63. PubMed ID: 15373093
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.